NOW ENROLLING

Clinical Trial in People With Stiff Person Syndrome (SPS)

A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in People With Treatment Refractory SPS



What is SPS?

SPS is an autoimmune neurological disorder that can affect nerves in the body. In SPS, the braking system of the nerves fails. Symptoms of SPS include stiffness, spasms, pain, and may include unsteady walking and falls.



Traditional treatments:

- 1 Treat symptoms, like muscle relaxers
- 2 Treat pain, like over the counter pain relievers
- 3 Treat the immune system, like IVIg (intravenous immunoglobulin)

The goal of treatment is to reduce spasms, stiffness, and pain. Your doctor can discuss with you the variety of treatment options for SPS, including the benefits and risks of such options.



What is CAR T-cell therapy?

KYV-101 is an investigational CAR T-cell therapy used in over 50 patients. KYV-101 works with your immune system to target the cells that harm your body, including unhealthy B cells that may contribute to disease activity in SPS.


This is the first study using KYV-101 in SPS, but several patients with SPS have been treated with KYV-101. Patients with Lupus Nephritis, Myasthenia Gravis, Systemic Sclerosis (Scleroderma), and Multiple Sclerosis have also been treated with KYV-101.



What is a Phase 2 clinical trial?

In a Phase 2 clinical trial, doctors want to understand if a treatment has a clinical benefit and confirm that it is safe and well tolerated in humans. A Phase 1 trial evaluates safety.

KYSA-8




About KYSA-8

The KYSA-8 trial is designed to evaluate if KYV-101 CAR T-cell therapy is effective and safe in people with SPS who have failed to improve with current medications.



Amanda Piquet, MD Director, Autoimmune Neurology University of Colorado School of Medicine Anschutz Medical Campus, CO





Marinos Dalakas, MD Director, Neuromuscular Division Thomas Jefferson University School of Medicine, PA




Anastasia Zekeridou, MD, PhD Co-Director Neuroimmunology Laboratory Associate Professor of Neurology Mayo Clinic, Rochester, MN

To learn more about this trial:

Visit: stiffpersonsyndrometrials.com Email: ClinicalTrialsInfo@kyvernatx.com





KYV-101 is an investigational therapy.

What will the **KYSA-8** study involve?



- Symptoms of CRS include fever, nausea, feeling tired (fatigue), and body aches and can progress in severity and may include low blood pressure, high fever, shock, and potentially organ failure.
- Symptoms of ICANS include fatigue, uncontrolled movements (tremors), impairment in thinking, loss of speech, muscle weakness, or more severe symptoms such as seizures and swelling in the brain.



To learn more about this trial:

Visit: stiffpersonsyndrometrials.com Email: ClinicalTrialsInfo@kyvernatx.com



KYV-101 is an investigational therapy. Copyright © 2024 Kyverna Therapeutics, Inc. 241213-XK-0038